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Abstract 
Purpose: To assess the prescribing and utilization pattern of vancomycin in Sultan Qaboos University 
Hospital (SQUH) in Oman.   
Methods:  A retrospective study that included in-patients at SQUH who had used vancomycin from 
January 1 2009 to December 31 2009 was conducted to determine the utilization patterns of the drug 
vis a vis to the Hospital Infection Control Practices Advisory Committee (HICPAC) guidelines and the 
North American Therapeutic Drug Monitoring Consensus (NATDMC) recommendations.  Information 
regarding patient characteristics and vancomycin therapy were obtained from patients’ medical records. 
Statistical analyses were performed using descriptive statistics. 
Results: Out of 478 prescriptions for 365 patients, 79.1 % were considered inappropriate, based on 
HICPAC guidelines. This was mainly due to the continuous use of vancomycin following negative 
microbiological cultures for β-lactam-resistant Gram-positive microorganisms. Vancomycin was 
prescribed mostly for treatment of sepsis (27.1 %), followed by prophylaxis against various clinical 
conditions (20.8 %). Therapeutic drug monitoring (TDM) practices at SQUH did not comply with 
NATDMC recommendations on the use of trough concentration in the specified range as a guide for 
monitoring of therapy.  
Conclusion: Irrational use of vancomycin was recorded in this study. The need for a restrictive policy 
and a revision of the current TDM in the setting are recommended..  
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The glycopeptide antibiotic, vancomycin, is 
effective against most Gram-positive bacteria 
especially Staphylococcus aureus and 
methicillin-resistant Staphylococcus aureus 
(MRSA). Such efficacy favored wide-scale use of 
vancomycin which later resulted in increase in 
bacterial resistance. Since the discovery of the 
first strains of vancomycin-resistant bacteria in 
the late 1980s, the incidence of resistant strains 
has been rising worldwide [1]. Among these 
resistant strains were vancomycin-resistant 
enterococci (VRE) and vancomycin-intermediate 
Staphylococcus aureus (VISA) [2]. The 
emergence of these strains was attributed to 
excessive and inappropriate use of vancomycin 
[1-3]. The Hospital Infection Control Practices 
Advisory Committee (HICPAC), a subcommittee 
of the United States’ Center for Disease Control 
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and Prevention (CDC), released a protocol on 
the proper use of vancomycin and managing 
patients infected with resistant bacteria [4-5]. 
These recommendations became widely 
accepted in many hospitals worldwide. 
Several studies evaluating the pattern of use of 
vancomycin have been conducted [6-8]. 
However, most of these were conducted in 
developed countries, and data on the utilization 
of vancomycin in developing regions remain 
sparse. Another significant limitation in many of 
these is the exclusion of TDM procedures 
recommended by the North American 
Therapeutic Drug Monitoring Consensus 
(NATDMC) from clinical practice [5]. . 
Vancomycin pharmacokinetics show large inter- 
and intra-individual variability for which serum 
drug assays are performed to ensure adequate 
therapy [5]. Proper use of TDM procedures along 
with appropriate prescription of vancomycin can 
help in preventing and controlling excessive use 
of vancomycin and the emergence of resistant 
microorganisms [9]. 
 
Thus, the purpose of this study was to evaluate 
the prescribing patterns and TDM of vancomycin 
at SQUH, a university teaching hospital in Oman, 
and to compare the results with the HICPAC 






Sultan Qaboos University Hospital (SQUH) is a 
518-bed tertiary-care hospital whose in-patient 
wards include four intensive care units (ICU), 
cardiac, oncology, neonatal, psychiatric, delivery, 
general medical, surgical and orthopedic wards. 
In addition, the hospital has bone marrow 
transplant and cardiothoracic units.  
 
In SQUH, vancomycin is regarded as a restricted 
antibiotic. An antibiotic handbook published by 
SQUH in 2006 is used as primary protocol for 
utilization of vancomycin and it is available to 
every prescriber in the hospital (Table 1). The 
indications for the use of the drug are almost 
similar to those of HICPAC recommendations. 
 
Study design   
 
The study was carried out by reviewing all 
medical records of patients who were admitted 
and received vancomycin during a 12-month 
period, from January 1st 2009 to December 31st 
2009. Ethical approval was sought and obtained 
from Sultan Qaboos University Medical Ethics 
Committee before commencing the study. 
Patients with missing clinical notes and/or no 
records of vancomycin utilization were excluded 
from the study. 
 
Table 1:  Recommended indications for the use of 
vancomycin in the antibiotic handbook of Sultan 
Qaboos University Hospital  
 
INDICATION 
• Methicillin resistant Staphylococcus aureus and 
methicillin-resistant Staphylcoccus epidermidis 
• Serious enterococcal infections. 
• Penicillin-resistant Streptococcus pneumonia 
(PRSP) infections . 
• Clostridium difficile antibiotic-associated colitis. 
• Central venous line infections caused by 
Staphylcoccus epidermidis and Staphylococcus 
aureus. 
• Acute fulminant (post operative) endophthalmitis. 
• Surgical prophylaxis in patients allergic to 
penicillin. 
• An alternative in infective endocarditis caused by 
enterococci or Staphylococcus aureus. 
• An alternative in cavernous sinus 
thrombophlebitis caused by Staphylococcus 
aureus. 
 
A data collection form was used to gather 
patients’ information. It included information 
about demographic data, history of drug allergy, 
co-morbidities, prescribing hospital unit, dosage 
regimen, co-medications, microbiological cultures 
and sensitivity testing, indication for use, 
application of TDM, clinical outcomes and 
reasons for discontinuation of therapy. 
 
Utilization and therapeutic drug monitoring 
studies 
 
Appropriate or inappropriate use of vancomycin 
was classified according to the guidelines issued 
by HICPAC. The TDM procedures applied in 
SQUH were compared to the TDM 
recommendations of NATDMC.  
 
At SQUH, the serum concentrations of 
vancomycin were measured by fluorescence 
polarization immunoassay using semiautomatic 
analyzer (Roche Diagnostic Systems, USA). 
SQUH guidelines recommend a trough and a 
peak vancomycin serum concentration of 5 – 10 
mg/L and 20 – 40 mg/L, respectively. The 
sampling time for peak and trough vancomycin 
serum concentration was drawn 1 h post-
vancomycin infusion and right before the next 
dose, respectively. Vancomycin was given in a 
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dose of 1000 mg every 12 h for patients with 
normal renal function and in a dose of  1000 mg 




SPSS version 16.0 (Chicago, IL, USA) was used 
to capture and analyze the data. Descriptive 
analysis was used to present the utilization of 
vancomycin and TDM procedures. Chi square 
(χ2) and Fisher’s exact tests were used to 
evaluate the association between gender, age 
and hospital unit and the appropriate prescribing 
of vancomycin based on HICPAC guidelines. 
Continuous variables such as age were analyzed 
by Student’s t-test. P values < 0.05 were 






During the study period, vancomycin was 
prescribed 478 times to 365 patients. Of those 
patients, 53.2 % were > 18 years old with mean 
age and weight of 26.2 ± 24.3 years and 37.6 ± 
28.2 kg, respectively. The male/female gender 
ratio was 1.1:1. The average dose of vancomycin 
given was 1066.1 ± 691.1 mg with an average 
duration of 7.2 ± 6.9 days. Almost all patients 
received vancomycin intravenously (98.5 %). 
Other clinical characteristics of the studied 




According to the HICPAC guidelines, 
vancomycin prescription was justified in only 
20.9% (n = 100) of the cases. There was 
discontinuation of the vancomycin therapy if 
microbiological cultures results were negative 
(63.0 %, n = 63), treatment of infections caused 
by β –lactam resistant Gram-positive bacteria 
(18.0 %, n = 18) and infections caused by Gram-
positive microorganisms in patients who are 
allergic to β–lactam antibiotics (10.0 %, n = 10). 
Failure to discontinue vancomycin upon receiving 
reports with negative cultures for β-lactam-
resistant microorganisms accounted for most of 
the inappropriate prescriptions (48.4 %, n = 183). 
Other inappropriate uses of vancomycin were 
prophylactic use in patients requiring dialysis 
(16.4 %, n = 62), patients with indwelling 
catheters (8.2 %, n = 31) and for surgery in 
patients without β-lactam antibiotic allergies (2.9 
%, n = 11). There was no significant relationship 
between either demographic data or hospital unit 
and inappropriate prescribing of vancomycin. 
 
 
Table 2:  Clinical characteristics of patients receiving 




Hospital unit, n (%) 
 
 Hematology 122 (33.4) 
 Infectious diseases 43 (11.8) 
 Nephrology 43 (11.8) 
 Neurology  29 (7.9) 
 Oncology 28 (7.7) 
 Surgery 24 (6.6) 
 Cardiology 24 (6.6) 
 Others 28 (7.7) 
 
Dose (mg), mean (±SD) 
 
 Prophylactic 1069.1 (451.7) 
 Therapeutic 1065.2 (743.4) 
 
Treatment duration (days), mean 
(±SD) 
 
 Prophylactic 2.2 (2.5) 
 Therapeutic 8.5 (7.2) 
 
Indication, n (%) 
 
 Sepsis 99 (27.1) 
 Prophylactic 76 (20.8) 
 Other febrile conditions 44 (12.1) 
 Pneumonia 29 (8.0) 
 Meningitis 15 (4.1) 
 Catheter-related infections 31 (8.5) 




 Acute chest syndrome 
(sickle cell disease) 
7 (2.0) 
 Others 48 (13.2) 
 
Cultures results, n (%) 
 
 Negative (no bacteria 
identified) 
278 (58.2) 










 Others 82 (17.2) 
  
Therapeutic drug monitoring 
 
Of the recruited cases, only 7.4 % (n = 23) 
complied with North American TDM consensus 
(NATDMC) of only collecting trough samples 
during the treatment course. Vancomycin serum 
trough concentrations were considered either 
sub-therapeutic (70.2 %, n = 158) or toxic (7.6 %, 
n = 17). In response to the reported toxic 
vancomycin concentrations, the initial dose was 
adjusted in 66.7 % of the cases.  
 
Based on SQUH TDM guidelines, 77.4 % (n = 
239) of the cases reported both peak and trough 
serum concentrations. Most of these were within 
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the local recommended target concentrations, 
i.e., 61.5 % (n = 147) for peak and 55.2 % (n = 
132) for trough.  
 
The dose was adjusted in 66 % of the cases 
where a toxic serum concentration is reported 
while it was only adjusted in 30 % of the cases 





Although vancomycin utilization in SQUH was 
more for the treatment of infections than 
prophylactic measures, it was found that only 
20.9 % of the prescriptions lie within the range of 
appropriate use as recommended by HICPAC. 
This finding is disturbing and may suggest a high 
degree of vancomycin misuse. Recent studies 
conducted in Western countries showed that 
inappropriateness in the use of vancomycin did 
not exceed 40 % of guidelines recommendations 
even in the absence of restriction policies [10-
11]. At SQUH, the prevalence of β-lactam-
resistant Gram-positive microorganisms and 
infections by MRSA, compared to what is 
reported in most Western countries, is low [12]. 
Thus, during the study period, only 18 cases 
were infected with MRSA and all were 
successfully treated with vancomycin. A similar 
finding has been reported for Kingdom of Saudi 
Arabia, a neighboring country [13].  Regardless 
of this, most of the inappropriateness arose from 
the continuous use of vancomycin despite 
receiving negative microbiological culture results 
for β-lactam-resistant Gram-positive 
microorganisms. Possible explanation for this 
practice is that physicians may have decided to 
continue empirical use of vancomycin as MRSA 
might have been undetected in cultures, an 
indication of lack of awareness of rational use of 
antibiotics. Another reason for continuing 
vancomycin as empirical therapy after culture 
results were available is convenience of use, as 
its spectrum covers many Gram-positive 
bacteria. Such trends have been observed in 
other developing nations as well [14].  
 
Among the other types of inappropriate use of 
vancomycin were prophylaxis for infections 
caused by catheter insertions in hemodialysis 
and peritoneal dialysis, surgical prophylaxis, 
treatment of Enterococci-related infections and 
treatment of infections associated with acute 
chest syndrome in sickle cell disease. VRE is 
consistently isolated in patients undergoing 
chronic dialysis especially in those who had 
previous exposure to vancomycin [15]. 
Additionally, the use of vancomycin in catheter-
related infections and surgical prophylaxis is 
indicated only in patients who are allergic to β–
lactam antibiotics [15]. Thus, the use of 
vancomycin for the treatment of catheter-
insertions related infections is not justified. One 
of the strategies to limit the spread of VRE is not 
to use vancomycin in the treatment of 
Enterococci-related infections [2]. However, this 
practice was still found in our study. Vancomycin 
was frequently used for prophylaxis of infections 
caused by catheter insertions in the nephrology 
department. In contrast to other hospitals in 
various countries, the major use of vancomycin 
was for surgical prophylaxis [6]. Hematology 
department, however, was the highest prescriber 
of therapeutic vancomycin, a finding similarly 
reported elsewhere [7,10]. It was utilized for 
treatment of sepsis and catheter-related 
infections. 
 
NATDMC recommends the use of trough 
concentration for monitoring of vancomycin [5]. 
This is because vancomycin follows a time-
dependent kinetic profile and nephrotoxicity 
appears to be associated with specific risk 
factors such as continuous infusion of 
vancomycin and concurrent use of loop diuretics 
and aminoglycosides [16]. The adopted 
recommended trough vancomycin serum 
concentration range at SQUH is lower than that 
currently recommended by NATDMC. Such 
discrepancy explains why most of the reported 
serum vancomycin concentrations in both 
prophylactic and therapeutic groups lie below the 
therapeutic range. It might also be due to low 
compliance with the usage recommendations. 
Recent investigations reveal that for adequate 
vancomycin therapy and to limit the emergence 
of resistance, trough vancomycin serum 
concentration needs to be higher than what was 
previously thought to be acceptable 
concentrations [5]. 
 
Vancomycin dosage was adjusted more 
frequently in cases that reported serum 
concentrations above the therapeutic range than 
subtherapeutic serum concentrations. 
Apparently, physicians are concerned more 
about the toxic effects of vancomycin than 
subtherapeutic levels. Although toxic vancomycin 
concentrations might cause adverse effects, 
subtherapeutic concentrations might lead to 
failure of therapy and emergence of resistance 
towards vancomycin [5]. Thus, in both situations, 
vancomycin dosage change should be 
considered. 
 
Limitations of the study 
 
Although we identified several areas that require 
improvement, such as TDM practice, healthcare 
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provider’s awareness, and revision of the current 
vancomycin utilization guidelines, unfortunately, 
this study did not address the other vancomycin-
related topics. Another major limitation was the 
nature of the study and the poor documentation 
in some of the cases. Thus, information such as 
adverse effects, outcome of vancomycin therapy 
and appropriate changes made after receiving 




The recorded irrational use of vancomycin 
indicates deficiencies in utilization practices at 
the level of study institute and perhaps the entire 
region. Such practices require further restrictive 
measures on vancomycin prescribing.  
Furthermore, the results of TDM review require a 
re-visit of the recommendation presented in the 
guidelines to parallel NATDMC guidelines. A 
further study is required to examine the outcome 
if the suggested revised recommendations and 
guidelines are implemented. 
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